METTL14 and pancreatic neoplasm: They reported that METTL14 was overexpressed in gemcitabine-resistant pancreatic cancer cells and p65 (a transcription factor) promoted the expression of METTL14 and subsequently upregulated cytidine deaminase (CDA), a gemcitabine inhibitor.